Mesoblast Limited MESO · NASDAQ
$12.41 +3.85% (+$0.46)
Summary
42 / 100 · Bulios Score
What speaks for it
- Revenue grew by 153% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 75% a year over 5 years. Over the last 3 years it grew by 153% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 5
- Hold 4
- Sell 2
Today's price within the analysts' price targets
The average target of $39 is 214% above today's price. 45% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2020By product
The company reports no revenue by product.
By region
- AUSTRALIA 100%
AUSTRALIA brings in 100% of revenue.
Segments in detail